Non-alcoholic fatty liver disease (NAFLD) and its more severe form of non-alcoholic steatohepatitis (NASH), typically arise in individuals who are obese. In these cases, typically weight loss is the treatment option. In recent years physicians have discovered a large proportion of non-obese individuals who develop NASH. This project was aimed at better understanding the disease process for non-obese NASH, as well as identifying pharmaceutical and nutritional methods to mitigate steatosis and inflammation in mouse models of NASH.